- 专利标题： Immune cells defective for Suv39h1
-
申请号： US17507748申请日： 2021-10-21
-
公开(公告)号： US11285176B2公开(公告)日： 2022-03-29
- 发明人: Sebastian Amigorena , Eliane Piaggio , Christel Goudot , Luigia Pace , Genevieve Almouzni , Leticia Niborski
- 申请人： INSTITUT CURIE , INSERM , Centre National de la Recherche Scientifique (CNRS
- 申请人地址： FR Paris; FR Paris; FR Paris
- 专利权人： INSTITUT CURIE,INSERM,Centre National de la Recherche Scientifique (CNRS
- 当前专利权人： INSTITUT CURIE,INSERM,Centre National de la Recherche Scientifique (CNRS
- 当前专利权人地址： FR Paris; FR Paris; FR Paris
- 代理机构： RinLaures LLC
- 代理商 Li-Hsien Rin-Laures; Kristen A. Dola
- 优先权： EP17305757 20170620
- 主分类号： A61K35/17
- IPC分类号： A61K35/17 ; A61P35/02 ; C07K14/725 ; C07K14/705 ; A61K45/06
摘要：
The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
信息查询
IPC分类:
